Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Guerbet
- Target Recruit Count
- 211
- Registration Number
- NCT01012674
- Locations
- 🇺🇸
Guerbet LLC, Bloomington, Indiana, United States
Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
- First Posted Date
- 2009-11-10
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Guerbet
- Target Recruit Count
- 222
- Registration Number
- NCT01010932
- Locations
- 🇺🇸
Guerbet LLC, Bloomington, Indiana, United States
Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time-Of-Flight (TOF)
- First Posted Date
- 2009-09-21
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Guerbet
- Target Recruit Count
- 13
- Registration Number
- NCT00980681
- Locations
- 🇺🇸
Guerbet LLC, Bloomington, Indiana, United States
DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in Patients With Abdominal or Lower Limb Arterial Diseases
Phase 4
Completed
- Conditions
- Peripheral Arterial Disease
- Interventions
- Other: Contrast-enhanced MRA - Imaging examination
- First Posted Date
- 2009-08-10
- Last Posted Date
- 2012-11-02
- Lead Sponsor
- Guerbet
- Target Recruit Count
- 20
- Registration Number
- NCT00955617
- Locations
- 🇫🇷
Guerbet, Roissy CDG Cedex, France
Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
Phase 3
Terminated
- Conditions
- Renal Artery Stenosis
- Interventions
- Other: Time of Flight Magnetic Resonance Angiography
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2016-05-20
- Lead Sponsor
- Guerbet
- Target Recruit Count
- 33
- Registration Number
- NCT00845702
- Locations
- 🇺🇸
Guerbet LLC, Bloomington, Indiana, United States
Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection
Withdrawn
- Conditions
- Nephrogenic Systemic FibrosisRenal Insufficiency
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Guerbet
- Registration Number
- NCT00811863
- Locations
- 🇺🇸
Radiology Consultants, Inc., Youngstown, Ohio, United States
Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography
Phase 4
Terminated
- Conditions
- Renal Impairment
- Interventions
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Guerbet
- Target Recruit Count
- 6
- Registration Number
- NCT00793182
- Locations
- 🇺🇸
Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸UAB Hospital, Birmingham, Alabama, United States
🇺🇸Providence Hospital, Washington, District of Columbia, United States
Renal Safety Evaluation After Dotarem®-Enhanced MRI
Phase 4
Completed
- Conditions
- Renal Insufficiency
- Interventions
- Drug: Dotarem®-enhanced MRIOther: non-enhanced MRI
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2015-06-09
- Lead Sponsor
- Guerbet
- Target Recruit Count
- 135
- Registration Number
- NCT00650845
- Locations
- 🇪🇸
Hospital San Carlos, Madrid, Spain
🇧🇪Alg. Inwendige Ziekten -Nierziekten, Roeselare, Belgium
🇫🇷Hôpital A. Calmette, Lille, France
A Clinical Study of Gadoteric Acid in Non-Coronary Magnetic Resonance (MR) Angiography
Phase 4
Completed
- Conditions
- Arterial Occlusive Disease
- First Posted Date
- 2007-03-15
- Last Posted Date
- 2008-11-26
- Lead Sponsor
- Guerbet
- Registration Number
- NCT00447889
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
A Clinical Study of Iobitridol in Patients Undergoing Multislice Computed Tomography (CT) Abdominal Angiography
Phase 4
Completed
- Conditions
- Diagnostic Imaging
- First Posted Date
- 2006-09-29
- Last Posted Date
- 2008-11-26
- Lead Sponsor
- Guerbet
- Registration Number
- NCT00382317
- Locations
- 🇦🇹
AKH, Vienna, Austria
🇫🇷CHU Charles Nicolle, Rouen, France
© Copyright 2025. All Rights Reserved by MedPath